drugset / Trial / NCT06816524

Summary

Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination. In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.

Timeline

Start
2026-01-05
Primary completion
2027-12-31
Completion
2028-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Measles-Rubella vaccine Vaccine
Subject R21-Matrix/M Vaccine (malaria vaccine) Vaccine